The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Costimulation Blockade with Belatacept in Renal Transplantation
Open accessAbstract
BACKGROUND: Renal transplantation is the standard of care for patients with end-stage renal disease. Although maintenance immunosuppression with calcineurin inhibitors yields excellent one-year survival, it is associated over the long term with high rates of death and graft loss, owing in part to the adverse renal, cardiovascular, and metabolic effects of these agents. The use of potentially less toxic agents, such as belatacept, a selective blocker of T-cell activation, may improve outcomes. METHODS: We randomly assigned renal-transplant recipients to receive an intensive or a less-intensive regimen of belatacept or cyclosporine. All patients received induction therapy with basiliximab, mycophenolate mofetil, and corticosteroids. The primary objective was to demonstrate the noninferiority of belatacept over cyclosporine in the incidence of acute rejection at six months (with an upper bound of the 95 percent confidence interval around the treatment difference of less than 20 percent). RESULTS: At six months, the incidence of acute rejection was similar among the groups: 7 percent for intensive belatacept, 6 percent for less-intensive belatacept, and 8 percent for cyclosporine. At 12 months, the glomerular filtration rate was significantly higher with both intensive and less-intensive belatacept than it was with cyclosporine (66.3, 62.1, and 53.5 ml per minute per 1.73 m2, respectively), and chronic allograft nephropathy was less common with both regimens of belatacept than with cyclosporine (29 percent, 20 percent, and 44 percent, respectively). Lipid levels and blood-pressure values were similar or slightly lower in the belatacept groups, despite the greater use of lipid-lowering and antihypertensive medications in the cyclosporine group. CONCLUSIONS: Belatacept, an investigational selective costimulation blocker, did not appear to be inferior to cyclosporine as a means of preventing acute rejection after renal transplantation. Belatacept may preserve the glomerular filtration rate and reduce the rate of chronic allograft nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Wolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033
Self-citationThe Natural History of Chronic Allograft Nephropathy
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020009 · Cited by 1,949
The Quality of Life of Patients with End-Stage Renal Disease
Evans, R. W., Manninen, D. L., Garrison, L. P., Hart, L. G., Blagg, C. R., Gutman, R. A., Hull, A. R., & Lowrie, E. G. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502283120905 · Cited by 1,183
Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report
Opelz, G., & Döhler, B. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00325.x · Cited by 1,081
Cancer after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D. T., & Wang, C. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00450.x · Cited by 1,071
Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
Self-citationLinsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
Comparison of Survival Probabilities for Dialysis Patients vs Cadaveric Renal Transplant Recipients
Port, F. K. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510110079036 · Cited by 825
Long-term survival in renal transplant recipients with graft function
Ojo, A. O., Hanson, J. A., Wolfe, R. A., Leichtman, A. B., Agodoa, L. Y., & Port, F. K. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00816.x · Cited by 810
Dantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B., & Soulillou, J.-P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08496-1 · Cited by 745
Self-citationLarsen, C. P., Pearson, T. C., Adams, A. B., Tso, P., Shirasugi, N., Strobertb, E., Anderson, D., Cowan, S., Price, K., Naemura, J., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00749.x · Cited by 723
Self-citationThe Role of T-Cell Costimulatory Activation Pathways in Transplant Rejection
Sayegh, M. H., & Turka, L. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382506 · Cited by 577
Kreis, H., Cisterne, J.-M., Land, W., Wramner, L., Squifflet, J.-P., Abramowicz, D., Campistol, J. M., Morales, J.-M., Grinyo, J.-M., Mourad, G., et al. (2000) · Transplantation · doi:10.1097/00007890-200004150-00009 · Cited by 536
Self-citationCreatinine Clearance: Bedside Estimate
JELLIFFE, R. W. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-4-604 · Cited by 489
Cardiovascular Toxicities of Immunosuppressive Agents
Miller, L. W. (2002) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2002.20902.x · Cited by 467
Johnson, R. W. G., Kreis, H., Oberbauer, R., Brattstrom, C., Claesson, K., & Eris, J. (2001) · Transplantation · doi:10.1097/00007890-200109150-00007 · Cited by 433
Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Linsley, P. S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.681 · Cited by 318
PREDICTING GLOMERULAR FILTRATION RATE AFTER KIDNEY TRANSPLANTATION
Nankivell, B. J., Gruenewald, S. M., Allen, R. D. M., & Chapman, J. R. (1995) · Transplantation · doi:10.1097/00007890-199506270-00007 · Cited by 292
Flechner, S. M., Kurian, S. M., Solez, K., Cook, D. J., Burke, J. T., Rollin, H., Hammond, J. A., Whisenant, T., Lanigan, C. M., Head, S. R., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00627.x · Cited by 281
Self-citationNatural History, Risk Factors, and Impact of Subclinical Rejection in Kidney Transplantation
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O’Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2004) · Transplantation · doi:10.1097/01.tp.0000128167.60172.cc · Cited by 271
Burdmann, E. A., Andoh, T. F., Yu, L., & Bennett, W. M. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00090-1 · Cited by 258
Gaspari, F., Ferrari, S., Stucchi, N., Centemeri, E., Carrara, F., Pellegrino, M., Gherardi, G., Gotti, E., Segoloni, G., Salvadori, M., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00579.x · Cited by 192
Application of newer clearance techniques for the determination of glomerular filtration rate
Gaspari, F., Perico, N., & Remuzzi, G. (1998) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199811000-00009 · Cited by 93
A single-centre experience of post-renal transplant lymphoproliferative disorder
Herzig, K. A., Juffs, H. G., Norris, D. L., Brown, A. M., Gill, D. S., Hawley, C. M., Cobcroft, R., Petrie, J. J. B., Marlton, P. V., Thomson, D. B., et al. (2003) · Transplant International · doi:10.1007/s00147-003-0596-0 · Cited by 41
Kode, R. K., Fa, K., Chowdhury, S., Ranganna, K. M., Fyfe, B. S., Stabler, S., Damask, A. M., Laftavi, M. R., Kumar, A. M., & PANKEWYCZ, O. G. (2003) · Clinical Transplantation · doi:10.1034/j.1399-0012.2003.00061.x · Cited by 21
Cited by
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Vincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Self-citationAutosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B.-S., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 832
Long-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Metadata
- Authors
- Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., Hagerty, D., Levy, E., Zhou, W., Natarajan, K., & Charpentier, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-08-25
- Volume
- 353
- Issue
- 8
- Pages
- 770-781
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2107346812
- Cited by
- 861
- References
- 29
- FWCI
- 34.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.